Linked Life Data

16670202

Source:http://linkedlifedata.com/resource/pubmed/id/16670202

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2006-6-26
pubmed:abstractText
Bisphosphonates are recommended to prevent skeletal related events (SREs) in patients with breast cancer and bone metastases (BCBM). However, their clinical and economic profiles vary from one agent to the other.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1072-82
pubmed:dateRevised
2007-5-8
pubmed:meshHeading
pubmed-meshheading:16670202-Bone Diseases, pubmed-meshheading:16670202-Bone Neoplasms, pubmed-meshheading:16670202-Breast Neoplasms, pubmed-meshheading:16670202-Computer Simulation, pubmed-meshheading:16670202-Cost-Benefit Analysis, pubmed-meshheading:16670202-Diphosphonates, pubmed-meshheading:16670202-Female, pubmed-meshheading:16670202-Great Britain, pubmed-meshheading:16670202-Humans, pubmed-meshheading:16670202-Life Expectancy, pubmed-meshheading:16670202-Models, Statistical, pubmed-meshheading:16670202-Multivariate Analysis, pubmed-meshheading:16670202-Outcome Assessment (Health Care), pubmed-meshheading:16670202-Pain, pubmed-meshheading:16670202-Quality of Life, pubmed-meshheading:16670202-Quality-Adjusted Life Years, pubmed-meshheading:16670202-Sensitivity and Specificity, pubmed-meshheading:16670202-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.
pubmed:affiliation
Pharmerit, Bethesda, MD 20814, USA. mbotteman@pharmerit.com
pubmed:publicationType
Journal Article